Walleye Trading
ARCT icon

Walleye Trading’s Arcturus Therapeutics ARCT Stock Holding History

Walleye Trading’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,700
Closed -$34.9K – 4096
2025
Q4 		$34.9K Buy
+5,700
New +$61.6K ﹤0.01% 4027

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Trading's ARCT Position: Q1 2026 in Review

Walleye Trading sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 5,700 shares — an estimated $34.9K sold.

Walleye Trading first reported a position in ARCT in Q4 2025 and held it in 1 quarter. The position peaked at $34.9K in Q4 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Walleye Trading reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 5,700 Arcturus Therapeutics shares in Q1 2026, an estimated $34.9K.
  • Walleye Trading first reported a position in Arcturus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Walleye Trading's Arcturus Therapeutics position peaked at $34.9K in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.